India · Delayed Price · Currency is INR OneSource Specialty Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw a 47% sequential revenue jump and a sharp EBITDA recovery, driven by semaglutide launches and capacity expansion. FY 2028 guidance of $400 million revenue and 40% EBITDA margin was reiterated, with strong demand and new approvals in key markets supporting future growth.
-
Q3 FY 2026 saw a 26% revenue decline due to delayed Canadian approvals, impacting DDC segment results and EBITDA. Despite near-term softness, robust demand, capacity expansion, and strong customer partnerships support confidence in achieving FY 2028 guidance of $400 million revenue and $160 million EBITDA.
-
Q2 FY26 saw 12% revenue growth and 37% EBITDA growth, with margins expanding to 28%. Capacity is fully sold out for DDCs, and biologics demand is surging, prompting accelerated expansion. FY 2028 revenue guidance is reiterated at $500 million, with strong global demand and ongoing regulatory uncertainties.
-
Q1 FY 2026 saw 12% revenue growth and a 37% rise in EBITDA, with strong performance in the DDC segment and robust customer demand driving accelerated capacity expansion. Strategic moves include evaluating acquisitions of Polish and Baroda facilities and a new partnership with Xbrane, positioning the company for significant growth in H2 and beyond.
Fiscal Year 2025
-
Q4 and FY 2025 saw robust revenue and EBITDA growth, driven by DDC and GLP projects, with strong compliance and customer additions. FY 2026 is expected to be transitional, with lumpy results ahead of major commercial launches in FY 2027–2028. Debt reduction, capacity expansion, and a strong order book support the $400M FY 2028 revenue target.
-
Q3 FY25 saw strong revenue and EBITDA growth, driven by biologics and DDC segments, with robust customer traction in GLP-1. Guidance targets 25%-30% CAGR and 40% EBITDA margin, supported by major capacity expansions and a solid balance sheet.